<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062779" LegacyPDQID="1974"><SummaryMetaData><SummaryType>Prevention</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about factors that may increase the risk of developing breast cancer and about research aimed at the prevention of this disease.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/breast/hp/breast-prevention-pdq">Breast Cancer (PDQ®): Prevention</SummaryURL><MainTopics><TermRef ref="CDR0000038832">breast cancer</TermRef></MainTopics><MainTopics><TermRef ref="CDR0000041588">cancer prevention</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Breast Cancer Prevention (PDQ®)</SummaryTitle><AltTitle TitleType="Short">Breast Cancer Prevention</AltTitle><SummarySection id="_558"><Title>Who Is at Risk?</Title><Para id="_559">Besides female sex, advancing age is the biggest risk factor for breast cancer.  Reproductive factors that increase exposure to endogenous estrogen, such as early menarche and late menopause, increase risk, as does the use of combination estrogen-progesterone hormones after menopause. Nulliparity and alcohol consumption also are associated with increased risk.</Para><Para id="_680">Women with a family history or personal history of invasive breast cancer, ductal carcinoma <Emphasis>in situ</Emphasis> or lobular carcinoma <Emphasis>in situ</Emphasis>, or a history of breast biopsies that show benign proliferative disease have an increased risk of breast cancer.</Para><Para id="_560">Increased breast density is associated with increased risk.  It is often a heritable trait but is also seen more frequently in nulliparous women, women whose first pregnancy occurs late in life, and women who use postmenopausal hormones and alcohol.</Para><Para id="_561">Exposure to ionizing radiation, especially during puberty or young adulthood, and the inheritance of detrimental genetic mutations increase breast cancer risk.</Para></SummarySection><SummarySection id="_1"><Title>Overview</Title><Para id="_2">Note: Separate PDQ summaries on <SummaryRef href="CDR0000062751" url="/types/breast/hp/breast-screening-pdq">Breast Cancer Screening</SummaryRef>; <SummaryRef href="CDR0000062787" url="/types/breast/hp/breast-treatment-pdq">Breast Cancer
Treatment</SummaryRef>; <SummaryRef href="CDR0000062745" url="/types/breast/hp/male-breast-treatment-pdq">Male Breast Cancer Treatment</SummaryRef>;  <SummaryRef href="CDR0000062770" url="/types/breast/hp/pregnancy-breast-treatment-pdq">Breast Cancer Treatment and Pregnancy</SummaryRef>; and <SummaryRef href="CDR0000304747" url="/publications/pdq/levels-evidence/screening-prevention">Levels of Evidence for Cancer Screening and Prevention Studies</SummaryRef> are
also available.
</Para><SummarySection id="_175"><Title>Factors With Adequate Evidence of Increased Risk of Breast Cancer</Title><SummarySection id="_562"><Title>Sex and age</Title><Para id="_563">Based on solid evidence, female sex and increasing age are the major risk factors for the development of breast cancer.</Para><Para id="_564"><Strong>Magnitude of Effect: Women have a lifetime risk of developing breast cancer that is approximately 100 times the risk for men.  The short-term risk of breast cancer in a 70-year-old woman is about ten times that of a 30-year-old woman.</Strong></Para><ItemizedList id="_565" Style="simple">
     <ListItem>Study Design: Many epidemiologic trials.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_566"><Title>Major inheritance susceptibility</Title><Para id="_567">Based on solid evidence, women who inherit gene mutations associated with breast cancer have an increased risk.</Para><Para id="_568"><Strong>Magnitude of Effect: Variable, depending on gene mutation, family history, and other risk factors affecting gene expression.</Strong></Para><ItemizedList id="_569" Style="simple">
     <ListItem>Study Design: Cohort or case-control studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_570"><Title>Breast density</Title><Para id="_571">Based on solid evidence, women with dense breasts have an increased risk of breast cancer. This is most often an inherent characteristic, to some extent modifiable by reproductive behavior, medications, and alcohol.<Reference refidx="1"/></Para><Para id="_572"><Strong>Magnitude of Effect: Women with dense breasts have increased risk, proportionate to the degree of density. This increased relative risk (RR) ranges from 1.79 for women with slightly increased density to 4.64 for women with very dense breasts, compared with women who have the lowest breast density.<Reference refidx="2"/></Strong></Para><ItemizedList id="_573" Style="simple">
     <ListItem>Study Design: Cohort, case-control studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_574"><Title>Modifiable Factors With Adequate Evidence of Increased Risk</Title><SummarySection id="_575"><Title>Combination hormone therapy</Title><Para id="_576">Based on  solid evidence,  combination hormone  therapy  (HT) (estrogen-progestin)  is associated with an increased risk of developing breast cancer.</Para><Para id="_577"><Strong>Magnitude of Effect: Approximately a 26% increase in incidence of invasive breast cancer; the number needed to produce one excess breast cancer is 237.</Strong></Para><ItemizedList id="_578" Style="simple">
     <ListItem>Study Design: Randomized controlled trials (RCTs).  Furthermore, cohort and ecological studies show that cessation of combination HT is associated with a decrease in rates of breast cancer. </ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_579"><Title>Ionizing radiation</Title><Para id="_580">Based on solid evidence, exposure of the breast to ionizing radiation is associated with an increased risk of developing breast cancer, starting 10 years after exposure and persisting lifelong. Risk depends on radiation dose and age at exposure, and is especially high if exposure occurs during puberty, when the breast develops.</Para><Para id="_581"><Strong>Magnitude of Effect: Variable but approximately a sixfold increase overall. </Strong></Para><ItemizedList id="_582" Style="simple">
     <ListItem>Study Design: Cohort or case-control studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_583"><Title>Obesity</Title><Para id="_584">Based on solid evidence, obesity is associated with an increased breast cancer risk in postmenopausal women who have not used HT. It is uncertain whether weight reduction decreases the risk of breast cancer in obese women.</Para><Para id="_585"><Strong>Magnitude of Effect: The Women's Health Initiative observational study of 85,917 postmenopausal women found body weight to be associated with breast cancer. Comparing women weighing more than 82.2 kg with those weighing less than 58.7 kg, the RR was 2.85 (95% confidence interval [CI], 1.81–4.49).</Strong></Para><ItemizedList id="_586" Style="simple">
     <ListItem>Study Design: Case-control and cohort studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_587"><Title>Alcohol</Title><Para id="_588">Based on solid evidence, alcohol consumption is associated with increased breast cancer risk in a dose-dependent fashion. It is uncertain whether decreasing alcohol intake by heavy drinkers reduces the risk.</Para><Para id="_589"><Strong>Magnitude of Effect: The RR for women consuming approximately four alcoholic drinks per day compared with nondrinkers is 1.32 (95% CI, 1.19–1.45). The RR increases by 7% (95% CI, 5.5%–8.7%) for each drink per day.</Strong></Para><ItemizedList id="_590" Style="simple">
     <ListItem>Study Design: Case-control and cohort studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_366"><Title>Factors With Adequate Evidence of Decreased Risk of Breast Cancer</Title><SummarySection id="_591"><Title>Early pregnancy</Title><Para id="_592">Based on solid evidence, women who have a full-term pregnancy before age 20 years have decreased breast cancer risk. </Para><Para id="_593"><Strong>Magnitude of Effect: 50% decrease in breast cancer, compared with nulliparous women or women who give birth after age 35 years.</Strong></Para><ItemizedList id="_594" Style="simple">
     <ListItem>Study Design: Case-control and cohort studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_595"><Title>Breast-feeding</Title><Para id="_596">Based on solid evidence, women who breast-feed have a decreased risk of breast cancer.</Para><Para id="_597"><Strong>Magnitude of Effect: The RR of breast cancer is decreased 4.3% for every 12 months of breast-feeding, in addition to 7% for each birth.</Strong><Reference refidx="3"/></Para><ItemizedList id="_598" Style="simple">
     <ListItem>Study Design: Case-control and cohort studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_599"><Title>Exercise</Title><Para id="_600">Based on solid evidence, exercising strenuously for more than 4 hours per week is associated with reduced breast cancer risk.</Para><Para id="_601"><Strong>Magnitude of Effect: Average RR reduction is 30% to 40%. The effect may be greatest for premenopausal women of normal or low body weight.</Strong></Para><ItemizedList id="_602" Style="simple">
     <ListItem>Study Design: Prospective observational and case-control studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_523"><Title>Estrogen use by women with prior hysterectomy</Title><SummarySection id="_661"><Title>Benefits</Title><Para id="_524">Based on fair evidence, women who have undergone a prior hysterectomy and who are treated with conjugated equine estrogen have a lower incidence of breast cancer. However, epidemiological studies yield conflicting results. </Para><Para id="_525"><Strong>Magnitude of effect: After 6.8 years, incidence was 23% lower in women treated with estrogen in an RCT (0.27% per year, with a median of 5.9 years of use, compared with 0.35% per year among those taking a placebo), but was 30% higher in women treated with estrogen in an observational study. The difference in these results may be explained by different screening behavior by the women in both studies.</Strong></Para><ItemizedList id="_526" Style="simple">
     <ListItem>Study Design: One RCT, observational studies.</ListItem><ListItem>Internal Validity:   Fair.</ListItem><ListItem>Consistency:  Poor.</ListItem><ListItem>External Validity: Poor.</ListItem></ItemizedList></SummarySection><SummarySection id="_662"><Title>Harms</Title><Para id="_604">Based on solid evidence, women who have undergone hysterectomy and who are taking postmenopausal estrogen have an increased risk of stroke and total cardiovascular disease.</Para><Para id="_605"><Strong>Magnitude of Effect: There is a 39% increase in the incidence of stroke (RR, 1.39; 95% CI, 1.1–1.77) and a 12% increase in cardiovascular disease (RR, 1.12; 95% CI, 1.01–1.24).</Strong></Para><ItemizedList id="_606" Style="simple">
     <ListItem>Study Design: RCTs, observational studies.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Poor.</ListItem></ItemizedList></SummarySection></SummarySection></SummarySection><SummarySection id="_115"><Title>Interventions With Adequate Evidence of Decreased Risk of Breast Cancer</Title><SummarySection id="_184"><Title> Selective estrogen receptor modulators (SERMs)</Title><SummarySection id="_669"><Title>Benefits</Title><Para id="_250">Based on solid evidence, tamoxifen and raloxifene reduce the incidence of breast cancer in postmenopausal women, and tamoxifen reduces the risk of breast cancer in high-risk premenopausal women. The effects observed for tamoxifen and raloxifene show persistence several years after active treatment is discontinued, with longer duration of effect noted for tamoxifen than for raloxifene.<Reference refidx="4"/></Para><Para id="_547">All fractures were reduced by SERMs, primarily noted with raloxifene but not with tamoxifen. Reductions in vertebral fractures (34% reduction) and small reductions in nonvertebral fractures (7%) were noted.<Reference refidx="4"/></Para><Para id="_386"><Strong>Magnitude of Effect: Tamoxifen reduced breast cancer by about 50%. Treatment with raloxifene has a similar effect on reduction of invasive breast cancer but appears to be less effective for the prevention of noninvasive tumors. A meta-analysis showed an overall 38% risk reduction for SERMs in breast cancer incidence. With 5 years of treatment, 42 women would need to be treated to prevent one breast cancer in the first 10 years of follow-up.<Reference refidx="4"/></Strong></Para><ItemizedList id="_251" Style="simple"><ListItem>Study Design: RCTs.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_670"><Title>Harms</Title><Para id="_609">Based on solid evidence, tamoxifen treatment increases the risk of endometrial cancer, which was apparent in the first 5 years of follow-up but not beyond; thrombotic vascular events (i.e., pulmonary embolism, stroke, and deep venous thrombosis); and cataracts. Many of these risks are reduced after active treatment with tamoxifen is discontinued. Based on solid evidence, raloxifene also increases venous pulmonary embolism and deep venous thrombosis but not endometrial cancer.</Para><Para id="_610"><Strong>Magnitude of Effect:  Meta-analysis showed RR of 2.4 (95% CI, 1.5–4.0) for endometrial cancer and 1.9 (95% CI, 1.4–2.6) for venous thromboembolic events. Meta-analysis showed the hazard ratio (HR) for endometrial cancer was 2.18 (95% CI, 1.39–3.42) for tamoxifen and 1.09 (95% CI, 0.74–1.62) for raloxifene. Overall, HR for venous thromboembolic events was 1.73 (95% CI, 1.47–2.05).</Strong></Para><ItemizedList id="_611" Style="simple">
     <ListItem>Study Design: RCTs.</ListItem><ListItem>Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_260"><Title>Aromatase inhibitors or inactivators</Title><SummarySection id="_667"><Title>Benefits</Title><Para id="_261">Based on solid evidence, aromatase inhibitors or inactivators (AIs) reduce the incidence of new breast cancers in postmenopausal women who have an increased risk.</Para><Para id="_388"><Strong>Magnitude of Effect: After a median follow-up of 35 months, women aged 35 years and older who had at least one risk factor (age  &gt;60 years, a Gail 5-year risk      &gt;1.66%, or ductal carcinoma <Emphasis>in situ</Emphasis> with mastectomy) and who took 25 mg of exemestane daily had a decreased risk of invasive breast cancer (HR,  0.35; 95% CI, 0.18–0.70).  The absolute risk reduction was 21 cancers avoided out of 2,280 participants over 35 months. The number needed to treat was about 100.<Reference refidx="5"/></Strong></Para><ItemizedList id="_291" Style="simple"><ListItem>Study Design:  One RCT.</ListItem><ListItem> Internal Validity: Good.</ListItem><ListItem>Consistency: One study in women with no history of breast cancer but consistent with RCTs in women with history of breast cancer.</ListItem><ListItem>External Validity: Good for women who meet inclusion criteria.</ListItem></ItemizedList></SummarySection><SummarySection id="_668"><Title>Harms</Title><Para id="_263">Based on fair evidence  from a single RCT of 4,560 women over 35 months, exemestane is associated with  hot flashes  and fatigue  but not with fractures, osteoporosis, or cardiovascular events, compared with placebo.<Reference refidx="5"/></Para><Para id="_389"><Strong>Magnitude of Effect: The absolute increase in hot flashes was 8% and the absolute increase in fatigue was 2%.</Strong></Para><ItemizedList id="_292" Style="simple"><ListItem>Study Design: One RCT.</ListItem><ListItem> Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good for women who meet inclusion criteria.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_186"><Title>Prophylactic mastectomy</Title><SummarySection id="_664"><Title>Benefits</Title><Para id="_187">Based on solid evidence, bilateral prophylactic mastectomy reduces the risk of breast cancer in women with a strong family history, and most women experience relief from anxiety about breast cancer risk.  There are no studies examining breast cancer outcomes in women who undergo contralateral prophylactic mastectomy after surgery for ipsilateral breast cancer.</Para><Para id="_390"><Strong>Magnitude of Effect: Breast cancer risk after bilateral prophylactic mastectomy in women at high risk is reduced as much as 90%, but published study designs may have produced an overestimate.</Strong></Para><ItemizedList id="_293" Style="simple"><ListItem>Study Design: Evidence obtained from case-control and  cohort studies.</ListItem><ListItem> Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_266"><Title>Prophylactic oophorectomy or ovarian ablation</Title><SummarySection id="_665"><Title>Benefits</Title><Para id="_267">Based on solid evidence, premenopausal women with <GeneName>BRCA</GeneName> gene mutations who undergo prophylactic oophorectomy have lower breast cancer incidence.   Similarly, oophorectomy or ovarian ablation is associated with decreased breast cancer incidence in normal premenopausal women and in women with increased breast cancer risk resulting from thoracic irradiation. </Para><Para id="_392"><Strong>Magnitude of Effect: Breast cancer incidence is decreased by 50%, but published study designs may have produced an overestimate.</Strong></Para><ItemizedList id="_295" Style="simple"><ListItem>Study Design: Observational, case-control, and cohort studies.</ListItem><ListItem> Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_666"><Title>Harms</Title><Para id="_617">Based on solid evidence, castration may cause the abrupt onset of menopausal symptoms such as hot flashes, insomnia, anxiety, and depression. Long-term effects include decreased libido, vaginal dryness, and decreased bone mineral density.</Para><Para id="_618"><Strong>Magnitude of Effect: Nearly all women experience some sleep disturbances, mood changes, hot flashes, and bone demineralization, but the severity of these symptoms varies greatly. </Strong></Para><ItemizedList id="_619" Style="simple">
     <ListItem>Study Design: Observational, case-control, and cohort studies.</ListItem><ListItem> Internal Validity: Good.</ListItem><ListItem>Consistency: Good.</ListItem><ListItem>External Validity: Good.</ListItem></ItemizedList></SummarySection></SummarySection></SummarySection><ReferenceSection><Citation idx="1" PMID="19107441">Boyd NF, Martin LJ, Rommens JM, et al.: Mammographic density: a heritable risk factor for breast cancer. Methods Mol Biol 472: 343-60, 2009.</Citation><Citation idx="2" PMID="16775176">McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (6): 1159-69, 2006.</Citation><Citation idx="3" PMID="12133652" MedlineID="22129315">Col: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (9328): 187-95, 2002.</Citation><Citation idx="4" PMID="23639488">Cuzick J, Sestak I, Bonanni B, et al.: Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381 (9880): 1827-34, 2013.</Citation><Citation idx="5" PMID="21639806">Goss PE, Ingle JN, Alés-Martínez JE, et al.: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364 (25): 2381-91, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_29"><Title>Description of the Evidence</Title><SummarySection id="_396"><Title>Background</Title><SummarySection id="_30"><Title>Incidence and mortality</Title><Para id="_31">With an estimated  231,840 cases expected, breast
cancer will be the most frequently diagnosed nonskin malignancy in U.S. women
in 2015.<Reference refidx="1"/>  Also in 2015, breast cancer will kill an estimated 40,290 
women, second only to lung cancer as a cause of cancer mortality in women. 
Breast cancer also occurs in men, and it is estimated that   2,350 new cases will be diagnosed in
2015.<Reference refidx="1"/>    Despite a prior long-term trend of gradually increasing breast cancer
incidence in women, data from the Surveillance, Epidemiology, and End Results 
Program show a decrease in breast cancer mortality of 1.9% per year from 1998 to 2007.<Reference refidx="2"/></Para><Para id="_624">The major risk factor for breast cancer is advancing age.  A 30-year-old woman has a 1 in 250 chance of being diagnosed with breast cancer in the next 10 years, whereas a 70-year-old woman has a 1 in 27 chance.<Reference refidx="2"/></Para><Para id="_679">Breast cancer incidence and mortality risk also vary on the basis of geography, culture, race, ethnicity, and socioeconomic status. Compared with other races, white women have a higher incidence of breast cancer that may be attributable, in part, to screening behavior.<Reference refidx="1"/></Para><Para id="_625">Screening by mammography decreases breast cancer mortality by identifying cases for treatment at an earlier stage. However, screening also identifies more cases than would become symptomatic in a woman’s lifetime, so screening increases breast cancer incidence. (Refer to the <SummaryRef href="CDR0000062751#_423" url="/types/breast/hp/breast-screening-pdq">Overdiagnosis</SummaryRef> section in the PDQ summary on <SummaryRef href="CDR0000062751" url="/types/breast/hp/breast-screening-pdq">Breast Cancer Screening</SummaryRef> for more information.)</Para></SummarySection><SummarySection id="_34"><Title>Etiology and pathogenesis of breast cancer</Title><Para id="_35">Breast cancer develops when a series of genetic mutations occurs.<Reference refidx="3"/>  Initially, mutations do not change the histologic appearance of the tissue, but accumulated mutations will result in hyperplasia, dysplasia, carcinoma <Emphasis>in situ</Emphasis>, and eventually, invasive cancer.<Reference refidx="4"/> The longer a woman lives, the more somatic mutations occur and the more likely it is that these mutations will produce populations of cells that will evolve into malignancies. Estrogen and progestin cause growth and proliferation of breast cells that may work through growth factors such as transforming growth factor (TGF)-alpha.<Reference refidx="5"/> These hormones, whether endogenous or exogenous, may promote the development and proliferation of breast cancer cells. 
</Para><Para id="_36">International variation in breast cancer rates may be explained by differences in genetics, reproductive factors, diet, exercise and screening behavior.  Some of these factors are modifiable, as evidenced by the observation that Japanese immigrants to the United States increase their breast cancer risk from lower Japanese levels to higher American levels within two generations.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/>
</Para></SummarySection><SummarySection id="_37"><Title>Endogenous estrogen</Title><Para id="_276">Many of the risk factors for breast cancer suggest that longer exposure to endogenous estrogen plays a role in the development of the disease. Women who experienced menarche at age 11 years or younger have about a 20% greater chance of developing breast cancer than do those who experienced menarche at age 14 years or older.<Reference refidx="9"/> Women who experience late menopause also have an increased risk. Women who develop breast cancer tend to have higher endogenous estrogen and androgen levels.<Reference refidx="10"/></Para><Para id="_38">Conversely, women who experience premature menopause have a lower risk of breast cancer.   Following ovarian ablation,
breast cancer risk may be reduced as much as 75% depending on age, weight, and parity, with the greatest reduction for young,
thin, nulliparous women.<Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/> The removal of one ovary
also reduces the risk of breast cancer but to a lesser degree than does the removal
of both ovaries.<Reference refidx="15"/>
</Para><Para id="_39">Other hormonal changes also
influence breast cancer risk.  (Refer to the <SummaryRef href="CDR0000062779#_428" url="/types/breast/hp/breast-prevention-pdq">Early pregnancy</SummaryRef> and <SummaryRef href="CDR0000062779#_430" url="/types/breast/hp/breast-prevention-pdq">Breast-feeding</SummaryRef> sections in the <SummaryRef href="CDR0000062779#_423" url="/types/breast/hp/breast-prevention-pdq">Factors With Adequate Evidence of Decreased Risk of Breast Cancer</SummaryRef> section of this summary for more information.)</Para><Para id="_626">The interaction of endogenous estrogen levels, insulin levels, and obesity—all of which affect breast cancer risk—are poorly understood but suggest strategies for interventions to decrease that risk.  It is likely that reproductive risk factors interact with predisposing genotypes. For example, in the Nurses’ Health Study,<Reference refidx="16"/> the associations between age at first birth, menarche, and menopause and the development of breast cancer were observed only among women without a family history of breast cancer in a mother or sister.</Para></SummarySection><SummarySection id="_43"><Title>Major inheritable susceptibility  </Title><Para id="_44">The inherited genetic profile of an individual influences susceptibility to mutagens and growth factors, which initiate or promote the carcinogenic process. (Refer to the <SummaryRef href="CDR0000062779#_149" url="/types/breast/hp/breast-prevention-pdq">Ionizing radiation exposure</SummaryRef> section in the <SummaryRef href="CDR0000062779#_410" url="/types/breast/hp/breast-prevention-pdq">Factors With Adequate Evidence of Increased Risk of Breast Cancer</SummaryRef> section of this summary for more information.) Known genetic syndromes related to specific aberrant alleles account for approximately 5% of breast cancers.  (Refer to the  PDQ summary on <SummaryRef href="CDR0000062855" url="/types/breast/hp/breast-ovarian-genetics-pdq">Genetics of Breast and Gynecologic Cancers</SummaryRef> for more information.)</Para><Para id="_45">  Women who inherit a deleterious mutation in <GeneName>BRCA1</GeneName> <Reference refidx="17"/><Reference refidx="18"/>
or <GeneName>BRCA2</GeneName> <Reference refidx="19"/> have an increased lifetime risk of breast cancer  (which occurs at a younger age), ovarian cancer, and
possibly colon cancer.  Deleterious <GeneName>BRCA2</GeneName> mutations are less common than <GeneName>BRCA1</GeneName> <Reference refidx="20"/>   mutations; <GeneName>BRCA2</GeneName> mutations are also associated with male breast cancer, prostate cancer, pancreatic cancer, and lymphomas.<Reference refidx="21"/>
</Para></SummarySection></SummarySection><SummarySection id="_410"><Title>Factors With Adequate Evidence of Increased Risk of Breast Cancer</Title><SummarySection id="_416"><Title>Hormone therapy</Title><Para id="_480">Based on a 1997 reanalysis of 51 epidemiological studies encompassing more than 150,000 women,  hormone therapy (HT) after menopause was shown to be associated with increased  breast cancer risk.<Reference refidx="22"/></Para><Para id="_481">The Heart and Estrogen/Progestin Replacement Study supported this finding  in 2002.<Reference refidx="23"/> In this study, 2,763 women with coronary heart disease who had a mean age of 67 years were randomly assigned to receive either estrogen and progestin therapy or placebo. After a mean follow-up of 6.8 years, the relative risk (RR) for breast cancer was 1.27 (95% confidence interval [CI], 0.84–1.94). Although not statistically significant, the RR estimate is consistent with the much larger  Women’s Health Initiative (WHI), also published in 2002.</Para><Para id="_482">The WHI investigated the effect of hormones and dietary interventions on heart disease and breast cancer risk.<Reference refidx="24"/> Women aged 50 to 79 years with intact uteri were randomly assigned to receive combined conjugated estrogen with continuous progestin (n = 8,506) or placebo (n = 8,102). The trial was terminated early because combined HT did not decrease coronary heart disease risk but did increase the risk of stroke and breast cancer. The increased breast cancer risk  (hazard ratio [HR], 1.24; 95% CI, 1.02–1.50)  was observed in all subgroups of women for invasive breast cancer but not for <Emphasis>in situ</Emphasis> breast cancer. The combined HT-related cancers had similar grade, histology, and expression of estrogen receptor (ER), progesterone receptor, and <GeneName>HER2</GeneName>/neu, with a trend toward larger size and higher incidence of lymph node metastases in the combined HT group.<Reference refidx="25"/> Extended follow-up  of a mean of 11 years showed higher breast cancer–specific mortality for the HT group (25 vs. 12 deaths, 0.03% vs. 0.01% per year; HR, 1.95; 95% CI, 1.0–4.04; <Emphasis>P</Emphasis> = .049). Combined HT was also associated with a higher percentage of abnormal mammograms.<Reference refidx="26"/></Para><Para id="_544">The WHI observational study was conducted in parallel with the WHI randomized controlled trial (RCT), recruiting postmenopausal women aged 50 to 79 years.  An analysis was conducted in the observational study of the WHI to further examine the  prognosis of women taking combination HT who were diagnosed with breast cancer and the risks based on time between menopause and initiation of HT. After a mean follow-up of 11.3 years,  the annualized incidence of breast cancer among women using estrogen plus progestin  was 0.60%, compared with 0.42% among nonusers (HR, 1.55; 95% CI, 1.41–1.70). Survival after the diagnosis of breast cancer was similar for combined HT users and nonusers.  Death from breast cancer was higher among combined HT users than among nonusers, but the difference was not statistically significant (HR, 1.3; 94% CI, 0.90–1.93).  Risks were highest among women initiating HT at the time of menopause, and risks diminished but persisted  with increasing time between menopause and starting combination HT.     All-cause mortality after the diagnosis of breast cancer was statistically significantly higher among combined HT users than among nonusers (HR, 1.87; 95% CI, 1.37–2.54.)  Overall, these findings were consistent with results from the RCT.<Reference refidx="27"/></Para><Para id="_511">The WHI also studied women who had previously undergone a hysterectomy and thus were not at risk for endometrial cancer, which is associated with unopposed estrogen therapy. Women aged 50 to 79 years (N = 10,739) were randomly assigned to receive conjugated equine estrogen (CEE) or placebo. This trial was also stopped early because of an increased risk of stroke and no improvement in a global risk-benefit index.<Reference refidx="28"/><Reference refidx="29"/> After an average 6.8 years of follow-up, breast cancer incidence was lower in the group receiving CEE (0.26% per year vs. 0.33%; HR, 0.77; 95% CI, 0.59–1.01). The global risk-benefit index was slightly worse for CEE.<Reference refidx="28"/> An extended follow-up for a median of 11.8 years included 78% of the trial participants.<Reference refidx="29"/><Reference refidx="30"/> Results seen in the initial study persisted, with a similar risk reduction for breast cancer in CEE recipients  (HR, 0.77; 95% CI, 0.62–0.95) <Reference refidx="29"/><Reference refidx="30"/> and a decrease in breast cancer mortality (6 vs. 16 deaths; HR, 0.37; 95% CI, 0.13–0.91). All-cause mortality was also lower in the CEE group (0.046% vs. 0.076% per year; HR, 0.62; 95% CI, 0.39–0.97). After CEE was discontinued, the risk of stroke decreased in the postintervention period. Over the entire follow-up period, there was no difference in the incidence of coronary heart disease, deep vein thrombosis, stroke, hip fracture, or colorectal cancer.<Reference refidx="29"/> Breast cancer incidence was similar for women who initiated CEE or placebo within the first 5 years after onset of menopause (HR, 1.06; 95% CI, 0.74–1.51).</Para><Para id="_535">A Danish trial of HT for 1,006 women entering menopause was designed to evaluate cardiovascular outcomes.  Combined HT (triphasic estradiol and norethisterone) was given to 407 women with intact uteri, and estradiol was given to 95 women who had undergone hysterectomy.  Controls (407 with intact uteri and 97 with hysterectomy) were not treated.  At 10 years, there was considerable contamination. Only one-half of the women assigned to the HT group were still taking the prescribed HT, and 22% of the control women had begun HT.  Cardiovascular outcomes favored HT-treated women, and there was no difference in breast cancer incidence.<Reference refidx="31"/></Para><Para id="_627">Observational studies augment the information obtained in RCTs.</Para><Para id="_512">The Million Women Study <Reference refidx="32"/> recruited 1,084,110 women aged 50 to 64 years in the United Kingdom between 1996 and 2001 and obtained information about HT use and other personal details.  The women were followed for breast cancer incidence and death.  One-half of the women had used HT.  At 2.6 years of follow up, there were 9,364 incidences of invasive breast cancers; at 4.1 years, there were 637 breast cancer deaths.  Current users of HT at recruitment were more likely than never-users to develop breast cancer (adjusted RR = 1.66; 95% CI, 1.58–1.75; <Emphasis>P</Emphasis> &lt; .0001) and to die from the disease (adjusted RR, 1.22; 95% CI, 1.00–1.48; <Emphasis>P</Emphasis> = .05). Past users of HT were, however, not at an increased risk of incident or fatal breast cancer (1.01 [95% CI, 0.94–1.09] and 1.05 [95% CI, 0.82–1.34], respectively). Incidence was significantly increased for current users of estrogen only (RR, 1.30; 95% CI, 1.21–1.40; <Emphasis>P</Emphasis> &lt; .0001), combined HT (RR, 2.00; 95% CI, 1.88–2.12; <Emphasis>P</Emphasis> &lt; .0001), and tibolone (RR, 1.45; 95% CI, 1.25–1.68; <Emphasis>P</Emphasis> &lt; .0001).  The magnitude of the associated risk was substantially greater for combined HT than for other types of HT (<Emphasis>P</Emphasis> &lt; .0001).</Para><Para id="_628">A population-based survey of 965 women with breast cancer and 1,007 controls was conducted by the Cancer Surveillance System of Puget Sound. It showed that combined HT users had a 1.7-fold increased risk of invasive breast cancer, whereas estrogen-only users did not.<Reference refidx="33"/></Para><Para id="_629">The association between the use of combined HT and increased breast cancer risk is consistent throughout all the trials. In contrast, the association between estrogen-only HT and breast cancer incidence is confusing because some studies show increased risk and some show protection.  It is possible that the timing of estrogen-only HT in relation to the onset of menopause is critical.  Furthermore, observational studies may not account for different screening behavior between HT users and nonusers, whereas RCTs, by design, will control that variable.<Reference refidx="34"/><Reference refidx="35"/></Para><Para id="_494">Following publication of the WHI results, HT use dropped dramatically in the United States and elsewhere.  Follow-up of WHI participants on the combined HT arm demonstrated a rapid decrease in the elevated breast cancer risk of therapy within 2 years, despite similar rates of mammography screening.<Reference refidx="36"/>   Analysis of changes in breast cancer rates in the United States  observed a sharp decline in breast cancer incidence rates from 2002 to 2003 among women aged 50 years and older, especially for estrogen receptor (ER)–positive cancers.<Reference refidx="37"/><Reference refidx="38"/> Similarly, in multiple  countries where  HT use was high, breast cancer rates decreased  in a similar time frame, coincident with decreases in prescribing patterns and/or reported prevalence of use.<Reference refidx="39"/>    <Reference refidx="40"/><Reference refidx="41"/>         A study among women receiving regular mammography screening supports that the observed sharp decline from 2002 to 2003 in breast cancer incidence was primarily caused by withdrawal of HT rather than declines in mammography rates.<Reference refidx="42"/>    After  the decline in breast cancer incidence  from 2002 to 2003, rates in the United States stabilized.<Reference refidx="42"/><Reference refidx="43"/>   </Para></SummarySection><SummarySection id="_149"><Title>Ionizing radiation exposure</Title><Para id="_150">A well-established relationship exists between exposure to ionizing radiation
and subsequent breast cancer.<Reference refidx="44"/>  Excess breast cancer risk has been  observed in association with atomic bomb exposure, frequent 
fluoroscopy for tuberculosis, and radiation therapy  for acne, tinea, thymic
enlargement, postpartum mastitis, and lymphoma.  Risk is higher for the young, especially around puberty.  An
estimate of the risk of breast cancer associated with medical radiology puts
the figure at less than 1% of the total.<Reference refidx="45"/> However, it has been theorized that
certain populations, such as <GeneName>AT</GeneName>  heterozygotes, are at
an increased risk of breast cancer from  radiation exposure.<Reference refidx="46"/> A large cohort study of women who carry mutations of <GeneName>BRCA1</GeneName> or <GeneName>BRCA2</GeneName> concluded that chest x-rays increase the risk of breast cancer even more (RR, 1.54; 95% CI, 1.1–2.1), especially for women who were x-rayed before age  20 years.<Reference refidx="47"/></Para><Para id="_151">Women treated for Hodgkin lymphoma by  age  16 years may have a subsequent risk, up to 35%, of
developing breast cancer by  age 40 years.<Reference refidx="48"/><Reference refidx="49"/>  Higher radiation doses  (median dose, 40 Gy in breast cancer cases) and
treatment  between the ages of 10 and 16 years are associated with   higher risk.<Reference refidx="48"/>    Unlike the risk for secondary leukemia, the risk of
treatment-related breast cancer does not abate with duration of follow-up, persisting more than 25 years after treatment.<Reference refidx="48"/><Reference refidx="50"/><Reference refidx="51"/> 
In these studies, most  patients  (85%–100%) who developed
breast cancer did so either within the field of radiation or at the
margin.<Reference refidx="48"/><Reference refidx="49"/><Reference refidx="50"/> A Dutch study examined 48 women who developed breast cancer at least 5 years after treatment for Hodgkin disease and  compared them with 175 matched female Hodgkin disease patients who did not develop breast cancer. Patients treated with chemotherapy and mantle radiation were less likely to develop breast cancer than were those treated with mantle radiation alone, possibly because of chemotherapy-induced ovarian suppression (RR, 0.06; 95% CI, 0.01–0.45).<Reference refidx="52"/> Another study of 105 radiation-associated breast cancer patients and 266  age-matched and radiation-matched controls showed a similar protective effect for ovarian radiation.<Reference refidx="51"/>  These studies suggest that ovarian hormones promote the proliferation of breast tissue with radiation-induced mutations.<Reference refidx="51"/>  </Para><Para id="_152">The question arises whether breast cancer patients treated with lumpectomy and radiation therapy
(L-RT) are at higher risk for second breast malignancies or other malignancies
than are  those treated by mastectomy.  Outcomes of 1,029 L-RT patients
were compared with  outcomes of 1,387 patients who underwent mastectomies. 
After a median follow-up of 15 years, there was no difference in the risk of
second malignancies.<Reference refidx="53"/>   Further evidence from three RCTs is also reassuring. One report of 1,851 women randomly assigned to undergo total mastectomy, lumpectomy alone, or L-RT showed rates of contralateral breast cancer to be 8.5%, 8.8%, and 9.4%, respectively.<Reference refidx="54"/>  Another study of 701 women randomly assigned to undergo radical mastectomy or breast-conserving surgery followed by radiation therapy demonstrated the rate of contralateral breast carcinomas per 100 woman-years to be 10.2 versus 8.7, respectively.<Reference refidx="55"/>  The third study compared 25-year outcomes of 1,665 women randomly assigned to undergo radical mastectomy, total mastectomy, or total mastectomy with radiation. There was no significant difference in the rate of contralateral breast cancer according to treatment group, and the  overall rate was 6%.<Reference refidx="56"/></Para></SummarySection><SummarySection id="_153"><Title>Obesity</Title><Para id="_154">Obesity is associated with increased breast cancer risk, especially among postmenopausal women who do not use HT. The WHI observed 85,917 women aged 50 to 79 years and collected information on weight history and known risk factors for breast cancer.<Reference refidx="57"/> Height, weight, and  waist and hip circumferences were measured.  With a median follow-up of 34.8 months, 1,030 of the women developed invasive breast cancer.  Among the women who never used HT, increased breast cancer risk was associated with weight at entry, body mass index (BMI) at entry, BMI at age 50 years,  maximum BMI, adult and postmenopausal weight change, and waist and hip circumferences.  Weight was the strongest predictor, with a RR of 2.85 (95% CI, 1.81–4.49) for women weighing more than 82.2 kg, compared with  those weighing less than 58.7 kg.</Para><Para id="_630">The association between obesity, diabetes, and insulin levels with breast cancer risk have been studied but not clearly defined.  The British Women’s Heart and Health Study of women aged 60 to 79 years compared 151 women who had a diagnosis of breast cancer with 3,690 women who did not.  The age adjusted odds ratio (OR) was 1.34 (95% CI, 1.02–1.77) for each unit increase in log(e) insulin level among nondiabetic women.  The association was observed, after adjustment for confounders and for potential mediating factors, and was seen for both pre- and postmenopausal breast cancers.  In addition, fasting glucose level, homeostatic model assessment score (the product of fasting glucose and insulin levels divided by 22.5), diabetes, and a history of gestational glycosuria or diabetes were also associated with breast cancer.<Reference refidx="58"/></Para></SummarySection><SummarySection id="_155"><Title>Alcohol</Title><Para id="_156">Alcohol consumption increases the risk of breast cancer.  A British meta-analysis included individual data from 53 case-control and cohort studies.<Reference refidx="59"/> Compared with the RR of breast cancer for women who reported no alcohol consumption, the RR of breast cancer was 1.32 (95% CI, 1.19–1.45; <Emphasis>P</Emphasis> &lt; .001) for women consuming 35 g to 44 g of alcohol per day and 1.46 (95% CI, 1.33–1.61; <Emphasis>P</Emphasis> &lt; .001) for those consuming at least 45 g of alcohol per day. The RR of breast cancer increases by about 7% (95% CI, 5.5%–8.7%; <Emphasis>P</Emphasis> &lt; .001) for each 10 g of alcohol (i.e., one drink) consumed per day. These findings persist after stratification for race, education, family history, age at menarche, height, weight, BMI, breast-feeding, oral contraceptive use, menopausal hormone use and type, and age at menopause.</Para></SummarySection></SummarySection><SummarySection id="_423"><Title>Factors With Adequate Evidence of Decreased Risk of Breast Cancer</Title><SummarySection id="_428"><Title>Early pregnancy</Title><Para id="_429">Childbirth is followed by an increase in risk of breast cancer for several years, and then a long-term reduction in risk, which is greater for younger women.<Reference refidx="14"/><Reference refidx="60"/><Reference refidx="61"/> In one study, women who experienced a first full-term pregnancy before age 20 years were half as likely to develop breast cancer as nulliparous women or women whose first full-term pregnancy occurred at age 35 years or older.<Reference refidx="62"/><Reference refidx="63"/> </Para></SummarySection><SummarySection id="_430"><Title>Breast-feeding</Title><Para id="_431">Breast-feeding is associated with a decreased risk of breast cancer.<Reference refidx="64"/>  A reanalysis of individual data from 47 epidemiological studies in 30 countries of 50,302 women with breast cancer and 96,973 controls revealed that breast cancer incidence was lower in parous women who had ever breast-fed than in parous women who had not.  It was also proportionate to duration of breast-feeding.<Reference refidx="65"/> The RR of breast cancer decreased by 4.3% (95%, CI, 2.9–5.8; <Emphasis>P</Emphasis> &lt; .0001) for every 12 months of breast-feeding in addition to a decrease of 7.0% (95% CI, 5.0–9.0; <Emphasis>P</Emphasis> &lt; .0001) for each birth.</Para></SummarySection><SummarySection id="_426"><Title>Exercise</Title><Para id="_427">Active exercise may reduce
breast cancer risk, particularly in young parous women.<Reference refidx="66"/> Numerous observational studies on  the relationship between the level of
physical activity and breast cancer risk have shown an inverse relationship.<Reference refidx="67"/>    The average RR reduction is  30% to 40%, but confounding variables—such as diet or a genetic predisposition to breast
cancer— have not been addressed.  A prospective study of more than 25,000 Norwegian women found that 
heavy manual labor or at least 4 hours of exercise  per week is associated with 
decreased  breast cancer risk, especially in
premenopausal women and those  of normal or lower-than-normal body weight.<Reference refidx="68"/> 
In a case-control study of African American women, strenuous recreational
physical activity more than 7 hours per week was associated with
decreased breast cancer incidence.<Reference refidx="69"/></Para></SummarySection></SummarySection><SummarySection id="_432"><Title>Interventions With Adequate Evidence of Benefit </Title><SummarySection id="_158"><Title>Selective estrogen receptor modulators (SERMs)</Title><Para id="_159">Data from adjuvant breast cancer trials using tamoxifen have shown that
tamoxifen not only suppresses the recurrence of breast cancer but also prevents
new primary contralateral breast cancers.<Reference refidx="70"/>  Tamoxifen also maintains bone density among postmenopausal women with breast cancer.<Reference refidx="71"/><Reference refidx="72"/><Reference refidx="73"/><Reference refidx="74"/><Reference refidx="75"/>  Adverse effects include hot flashes, venous thromboembolic events, and endometrial cancer.<Reference refidx="76"/><Reference refidx="77"/><Reference refidx="78"/>  </Para><Para id="_160">These adjuvant trial results were the basis for the Breast Cancer Prevention Trial (BCPT) that randomly assigned 13,388 patients at elevated risk of breast cancer  to receive  tamoxifen or placebo.<Reference refidx="79"/><Reference refidx="80"/> 
  The  study was closed early because of a 49% reduction in the
incidence of breast cancer for the tamoxifen group (85 vs. 154 invasive breast cancer cases and 31 vs. 59 <Emphasis>in situ</Emphasis> cases at 4 years). Tamoxifen-treated women also had fewer fractures (47 vs. 71) but more endometrial cancer (33 vs. 14 cases) and thrombotic events (99 vs. 70), including pulmonary emboli (17 vs. 6).<Reference refidx="80"/>  </Para><Para id="_299">An update of the BCPT  results after 7 years of follow-up demonstrated results similar to those in the initial report.<Reference refidx="81"/> There were some dropouts among women in the placebo arm; some of them enrolled in a subsequent trial, so new women were added to the placebo group.      Benefits and risks of tamoxifen were not significantly different from those in the original report, with persistent benefit of fewer fractures and persistent increased risk of endometrial cancer, thrombosis, and cataract surgery.                      No overall mortality benefit was observed after 7 years of follow-up (RR, 1.10; 95% CI, 0.85–1.43).</Para><Para id="_631">Three other trials of tamoxifen for primary prevention of breast cancer have been completed.<Reference refidx="82"/><Reference refidx="83"/><Reference refidx="84"/></Para><ItemizedList id="_671" Style="bullet" Compact="No">
     <ListItem>A study in the United Kingdom <Reference refidx="82"/>
focused on 2,471 women at increased breast cancer risk because of their family
history of breast and/or ovarian cancer.  After a median follow-up of nearly 6 years, no protective
effect of tamoxifen was detected (RR, 1.06), but there was a slight  reduction in breast cancer risk in the tamoxifen arm  (HR,  0.78; 95% CI, 0.58–1.04) at a median  of 13 years. However, risk of ER-positive breast cancer was significantly reduced in the treatment arm (HR, 0.61; 95% CI, 0.43–0.86), an effect noted predominantly in the posttreatment period.<Reference refidx="85"/></ListItem><ListItem>An Italian study <Reference refidx="83"/> focused on 5,408
women who had undergone hysterectomy and who were described as low to normal
risk. After a median follow-up of nearly 4 years, no protective effect of tamoxifen was observed.  Longer follow-up and subgroup analysis in this trial found a protective effect of tamoxifen among women at high risk for hormone receptor–positive breast cancer (RR, 0.24; 95% CI, 0.10–0.59) and among women who were taking HT during the trial (RR, 0.43; 95% CI, 0.20–0.95).<Reference refidx="86"/><Reference refidx="87"/></ListItem><ListItem>The   International Breast Cancer Intervention Study (IBIS-I) randomly assigned 7,152 women aged 35 to 70  years who were at increased risk of breast cancer to receive tamoxifen (20 mg/day ) or placebo for 5 years.<Reference refidx="84"/>   After a median follow-up of 50 months, fewer tamoxifen-treated women  had developed invasive or <Emphasis>in situ</Emphasis> breast cancer (absolute rate, 4.6 vs. 6.75  per 1,000 woman-years;  risk reduction, 32%; 95% CI, 8%–50%). The RR   reduction in ER-positive invasive breast cancer was 31%; there was no reduction in  ER-negative cancers. There was an excess of all-cause mortality in the tamoxifen group (25 vs. 11; <Emphasis>P</Emphasis> = .028), which the authors attributed to chance. The beneficial effect of tamoxifen on breast cancer persisted after active treatment, with a median posttherapy follow-up of 46 months; 27% fewer women in the tamoxifen arm developed breast cancer (142 vs. 195 cases, respectively; RR, 0.73, 95% CI, 0.58–0.91).<Reference refidx="88"/> </ListItem></ItemizedList><Para id="_231">A meta-analysis  of these primary prevention tamoxifen trials showed  a 38% reduction in the incidence of breast cancer without statistically significant heterogeneity.<Reference refidx="78"/>  ER-positive    tumors were reduced by 48%.  Rates of endometrial cancer were increased (consensus RR, 2.4; 95% CI, 1.5–4.0), as were venous thromboembolic events (RR, 1.9; 95% CI, 1.4–2.6).  None of these primary prevention trials was designed to detect differences in breast cancer mortality. </Para><Para id="_163">Women with a history of ductal carcinoma <Emphasis>in situ</Emphasis> (DCIS) are at increased risk
 for contralateral breast cancer. The National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-24 addressed their management. Women were randomly assigned to receive lumpectomy and radiation therapy (L-RT) either with or without adjuvant tamoxifen.  At 6 years, the tamoxifen-treated women had fewer invasive and <Emphasis>in situ</Emphasis> breast cancers (8.2% vs. 13.4%; RR, 0.63; 95% CI, 0.47–0.83).   The risk of contralateral breast cancer was also lower in women treated with tamoxifen (RR, 0.49; 95% CI, 0.26 – 0.87).<Reference refidx="89"/></Para><Para id="_165">Raloxifene hydrochloride (Evista) is a SERM that has antiestrogenic effects on breast
 and estrogenic effects on bone, lipid metabolism, and
blood clotting. Unlike tamoxifen, it has antiestrogenic effects on the endometrium.<Reference refidx="90"/>  The Multiple Outcomes of Raloxifene Evaluation (MORE) trial was a
randomized, double-blind trial that evaluated 7,705 postmenopausal women with
osteoporosis from 1994 to 1998 at 180 clinical centers in the United States.  Vertebral fractures were reduced.  The
effect on breast cancer incidence was a secondary endpoint.    After a median follow-up of 47 months, the risk of invasive breast cancer
decreased in the raloxifene-treated women (RR, 0.25; 95% CI, 0.17–0.45).<Reference refidx="91"/>  As with tamoxifen, raloxifene
 reduced the risk of ER-positive breast cancer but not
ER-negative breast cancer and was associated with an excess risk of hot flashes and thromboembolic events.    No excess risk of endometrial cancer or hyperplasia was
observed after 47 months of follow-up.<Reference refidx="92"/></Para><Para id="_253">An extension of the MORE trial was the Continuing Outcomes Relevant to Evista (CORE) trial, which studied  about 80% of MORE participants in their randomized groups for an additional 4 years.      Although there was a median 10-month gap between the two studies, and only about 55% of women were adherent to their assigned medications, the raloxifene group continued to experience a lower incidence of invasive ER-positive breast cancer.    The overall reduction in invasive breast cancer during the 8 years of MORE and CORE was 66% (HR, 0.34; 95% CI, 0.22–0.50); the reduction for ER-positive invasive breast cancer was 76% (HR, 0.24; 95% CI, 0.15–0.40).<Reference refidx="93"/></Para><Para id="_466">The Raloxifene Use for the Heart trial was a randomized, placebo-controlled trial to evaluate the effects of raloxifene on incidence of coronary events and invasive breast cancer.  As in the MORE and CORE studies, raloxifene reduced the risk of invasive breast cancer (HR, 0.56; 95% CI, 0.38–0.83).<Reference refidx="94"/></Para><Para id="_328">The Study of Tamoxifen and Raloxifene (STAR) (NSABP P-2) compared tamoxifen and raloxifene in 19,747 high-risk women who were monitored for  a mean of 3.9 years.  Invasive breast cancer incidence was approximately the same for both drugs, but there were fewer noninvasive cancers  in the tamoxifen group. Adverse events of uterine cancer, venous thrombolic events, and cataracts were more common in tamoxifen-treated women, and there was no difference in ischemic heart disease events, strokes, or fractures.<Reference refidx="95"/> Treatment-associated symptoms of dyspareunia, musculoskeletal problems, and weight gain occurred less frequently in  tamoxifen-treated women, whereas vasomotor flushing, bladder control symptoms, gynecologic symptoms, and leg cramps occurred less frequently in those receiving raloxifene.<Reference refidx="96"/></Para><Table id="_332"><Title>Incidence of Outcomes Per 1,000 Women</Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry/><entry>Tamoxifen</entry><entry>Raloxifene</entry><entry>RR, 95% CI</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1">CI = confidence interval;      RR = relative risk; VTE = venous thromboembolism.</entry></Row></TFoot><TBody><Row><entry>Invasive breast cancer</entry><entry>4.3</entry><entry>4.41</entry><entry>1.02, 0.82–1.28</entry></Row><Row><entry>Noninvasive breast cancer</entry><entry>1.51</entry><entry>2.11</entry><entry>1.4, 0.98–2.00</entry></Row><Row><entry>Uterine cancer </entry><entry>2.0</entry><entry>1.25</entry><entry>0.62, 0.35–1.08</entry></Row><Row><entry>VTE</entry><entry>3.8</entry><entry>2.6</entry><entry>0.7, 0.68–0.99</entry></Row><Row><entry>Cataracts</entry><entry>12.3</entry><entry>9.72</entry><entry>0.79, 0.68–0.92</entry></Row><Row><entry NameEnd="col4" NameSt="col1"><Strong>Incidence of Symptoms (0–4 scale)</Strong></entry></Row><Row><entry NameEnd="col4" NameSt="col1">Favor Tamoxifen</entry></Row><Row><entry>Dyspareunia</entry><entry>0.68</entry><entry>0.78</entry><entry><Emphasis>P </Emphasis>&lt; .001</entry></Row><Row><entry>Musculoskeletal problems</entry><entry>1.10</entry><entry>1.15</entry><entry><Emphasis>P</Emphasis> = .002</entry></Row><Row><entry>Weight gain</entry><entry>0.76</entry><entry>0.82</entry><entry><Emphasis>P</Emphasis> &lt; .001</entry></Row><Row><entry NameEnd="col4" NameSt="col1">Favor Raloxifene</entry></Row><Row><entry>Vasomotor symptoms</entry><entry>0.96</entry><entry>0.85</entry><entry><Emphasis>P </Emphasis>&lt; .001</entry></Row><Row><entry>Bladder control symptoms</entry><entry>0.88</entry><entry>0.73</entry><entry><Emphasis>P </Emphasis>&lt; .001</entry></Row><Row><entry>Leg cramps</entry><entry>1.10</entry><entry>0.91</entry><entry><Emphasis>P </Emphasis>&lt; .001</entry></Row><Row><entry>Gynecologic problems</entry><entry>0.29</entry><entry>0.19</entry><entry><Emphasis>P </Emphasis>&lt; .001</entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_199"><Title>Aromatase inhibition or inactivation</Title><Para id="_200">Another class of agents that is commercially available for the treatment of women with hormone-sensitive breast cancer may also prevent breast cancer.  These  drugs interfere with  aromatase, the adrenal enzyme that allows   estrogen production in postmenopausal women.  Anastrozole  and letrozole  inhibit aromatase activity, whereas exemestane  inactivates the enzyme.  Side effects for all three drugs include  fatigue, arthralgia, myalgia, decreased bone mineral density, and increased fracture rate.  </Para><Para id="_201">All three drugs decrease the incidence of new breast cancers in women with a prior breast cancer diagnosis. In the Arimidex, Tamoxifen, Alone or in  Combination trial, comparing anastrozole to tamoxifen as adjuvant therapy for primary breast cancer, the rate of locoregional and distant recurrence was lower for anastrozole (7.1% vs. 8.5%) but higher for the combination (9.1%).<Reference refidx="97"/> Anastrozole was also more effective in preventing new contralateral breast cancer (0.4% vs. 1.1% vs. 0.9%).  </Para><Para id="_634">Another trial of 5,187 women who had received 5 years of adjuvant tamoxifen randomly assigned women to receive either letrozole or placebo.<Reference refidx="98"/> After only 2.5 years of median follow-up, the study was terminated because previously defined efficacy endpoints had been reached. Not only did letrozole-treated patients have a lower incidence of locoregional and distant cancer recurrence, they also had a lower incidence of new contralateral breast cancer (14 vs. 26). </Para><Para id="_635">A third trial randomly assigned 4,742 women who had received 2 years of adjuvant tamoxifen to either continue the tamoxifen or switch to exemestane.<Reference refidx="99"/> After 2.4 years of median follow-up, the exemestane group had a decreased risk of local or metastatic recurrence and a decreased incidence of new contralateral breast cancer (9 vs. 20).</Para><Para id="_202">A single RCT of primary prevention of breast cancer compared exemestane to placebo in 4,560 women with at least one risk factor (age &gt;60 years, a Gail 5-year risk &gt;1.66%, or a history of DCIS with mastectomy).  After 35 months of median follow-up, invasive breast cancer was diagnosed less frequently in the exemestane group (11 vs. 32; HR, 0.35; 95% CI, 0.18–0.70; number needed to treat, about 100 for 35 months). Compared with the placebo group, the exemestane-treated women had more hot flashes (increase, 8%) and fatigue (increase, 2%) but no difference in fractures or cardiovascular events.<Reference refidx="100"/></Para><Para id="_554">The International Breast Cancer Intervention Study II (IBIS-II) randomly assigned 3,864 postmenopausal women who were at increased risk of developing breast cancer to receive either daily anastrazole (1 mg) or placebo for 5 years.<Reference refidx="101"/>    The definition of high risk varied by age and was defined by the RR compared with the general population:  women aged 40 to 44 years  had to have an RR of at least 4; women aged 45 to 60 years  had to have an RR of 2.0; and women aged 60 to 70 years  had to have an RR of at least 1.5.   Alternatively, women with an estimated 10-year risk rate of developing breast cancer of at least 5%  (per the Tyer-Cuzick model) were eligible for inclusion.  Women with DCIS diagnosed within 6 months and treated with unilateral mastectomy were eligible for the trial, and 326 were assigned randomly.    After a median follow-up of 5 years, fewer breast cancers (invasive and DCIS) occurred in the anastrazole-treated group than in the placebo group (HR, 0.47; 95% CI, 0.32–0.68).  The risk of hormone receptor–positive, but not hormone receptor–negative, forms of breast cancer was reduced.   Based on predicted cumulative incidence over 7 years, the number of high-risk women (per the IBIS-II eligibility criteria) needed to treat for 5 years to prevent one breast cancer in 7 years of follow-up was estimated to be 36 (95% CI, 33–44).  Women treated with anastrazole were more likely than those taking placebo to have musculoskeletal symptoms, including arthralgias (51% vs. 46%), joint stiffness (7% vs. 5%), pain in hand or foot (9% vs. 8%) , and carpal tunnel syndrome (3% vs. 2%);  hypertension (5% vs. 3%);  vasomotor symptoms (57% vs. 49%);  and dry eyes (4% vs. 2%).  The association between hand or foot pain with anastrazole treatment was of borderline statistical significance; all other side effects noted above were statistically significantly associated with anastrazole treatment.  </Para></SummarySection><SummarySection id="_166"><Title>Prophylactic mastectomy</Title><Para id="_167">A retrospective cohort study evaluated the impact of bilateral prophylactic mastectomy on breast cancer incidence among women at high and moderate risk on the basis of family history.<Reference refidx="102"/> <GeneName>BRCA</GeneName> mutation status was not known. Subcutaneous, rather than total, mastectomy was performed in 90% of these women.  After a median follow-up of 14 years postsurgery, the risk reduction for the 425 moderate-risk women was 89%; for the 214 high-risk women, it was 90% to 94%, depending on the method used to calculate expected rates of breast cancer. The risk reduction for breast cancer mortality was 100% for moderate-risk women and 81% for high-risk women. This study probably overestimated breast cancer risk on the basis of family history rather than genetic studies.</Para><Para id="_689">The rate of bilateral mastectomy among women with unilateral disease (DCIS and early-stage invasive breast cancer) was reported to have increased from 1.9% in 1998 to 11.2% in 2011 based on data from the U.S. National Cancer Data Base.<Reference refidx="103"/></Para><Para id="_636">No studies have been done on the benefits of prophylactic mastectomy in the average-risk population to prevent contralateral breast cancer in women with an ipsilateral breast cancer.</Para></SummarySection><SummarySection id="_193"><Title>Prophylactic oophorectomy</Title><Para id="_194">Ovarian ablation and oophorectomy are associated with decreased breast cancer risk in normal women and in women with increased risk resulting from thoracic irradiation.  (Refer to the <SummaryRef href="CDR0000062779#_37" url="/types/breast/hp/breast-prevention-pdq">Endogenous estrogen</SummaryRef> section in the  <SummaryRef href="CDR0000062779#_29" url="/types/breast/hp/breast-prevention-pdq">Description of the Evidence</SummaryRef> section of this summary for more information.) Observational studies of women with high breast cancer risk due to <GeneName>BRCA1</GeneName> or <GeneName>BRCA2</GeneName> gene mutations showed that prophylactic oophorectomy to prevent ovarian cancer was also associated with a 50% decrease in breast cancer incidence.<Reference refidx="104"/><Reference refidx="105"/><Reference refidx="106"/> These studies are confounded by selection bias, family relationships between patients and controls, indications for oophorectomy, and inadequate information about hormone use.  A prospective cohort study had similar findings, with a greater breast cancer risk reduction in <GeneName>BRCA2</GeneName> mutation carriers than in <GeneName>BRCA1</GeneName> carriers.<Reference refidx="107"/></Para></SummarySection></SummarySection><SummarySection id="_433"><Title>Factors and Interventions With Inadequate Evidence of an Association</Title><SummarySection id="_434"><Title>Oral contraceptives</Title><Para id="_435">Oral contraceptives have been associated with a small  increased risk of breast cancer in current users  that  diminishes over time.<Reference refidx="108"/>  A well-conducted case-control study did not observe an association between breast cancer risk and oral contraceptive use for every use, duration of use, or recency of use.<Reference refidx="109"/></Para><Para id="_436">Another case-control study found no increased risk of breast cancer associated with the use of injectable or implantable progestin-only contraceptives in women aged 35 to 64 years.<Reference refidx="110"/></Para></SummarySection><SummarySection id="_283"><Title>Environmental factors</Title><Para id="_284">Occupational, environmental, or chemical exposures have been proposed as causes of  breast cancer. Although some findings suggest
that organochlorine exposures, such as those associated with insecticides,
might be associated with an increase in breast cancer risk,<Reference refidx="111"/><Reference refidx="112"/> other 
case-control and nested case-control studies do not.<Reference refidx="113"/><Reference refidx="114"/><Reference refidx="115"/><Reference refidx="116"/><Reference refidx="117"/><Reference refidx="118"/>  Studies reporting positive associations have been inconsistent in the identification of responsible organochlorines. Some of these substances have weak estrogenic effects, but their effect on breast cancer risk remains unproven. The use of dichloro-diphenyl-trichloroethane  was banned in the United States in 1972, and the production of  polychlorinated biphenyls  was stopped in 1977.</Para></SummarySection></SummarySection><SummarySection id="_642"><Title>Factors and Interventions With Adequate Evidence of No Association</Title><SummarySection id="_643"><Title>Abortion</Title><Para id="_644">Abortion has been proposed as a cause of breast cancer, and the possible association has been used as an argument against abortion. However, the studies that were cited to demonstrate an association had used recalled information in populations where induced abortion had a social or religious stigma. Subsequently, a meta-analysis demonstrated that women with breast cancer were more likely to report prior abortions than were control women, whereas both groups reported prior miscarriages equally.  It also showed no association between either abortion or miscarriage and breast cancer if the data was collected prospectively.<Reference refidx="119"/> Importantly, an association with breast cancer was not shown in seven trials conducted in social environments where abortion is accepted <Reference refidx="120"/><Reference refidx="121"/><Reference refidx="122"/><Reference refidx="123"/><Reference refidx="124"/><Reference refidx="125"/><Reference refidx="126"/> or in four trials that collected abortion data prospectively.<Reference refidx="127"/><Reference refidx="128"/><Reference refidx="129"/><Reference refidx="130"/></Para></SummarySection><SummarySection id="_645"><Title>Diet and vitamins</Title><Para id="_647">Despite enthusiasm for dietary manipulations and vitamin ingestion to prevent breast cancer, there is no evidence that these interventions are effective.</Para><Para id="_648">A summary of ecologic studies published before 1975 showed a positive correlation between international age-adjusted breast cancer mortality rates and the estimated per capita consumption of dietary fat.<Reference refidx="131"/> Results of case-control studies have been mixed.  Twenty years later, a pooled analysis of results from seven cohort studies found no association between total dietary fat intake and breast cancer risk.<Reference refidx="132"/></Para><Para id="_649">A randomized controlled dietary modification study was undertaken among 48,835 postmenopausal women aged 50 to 79 years who were also enrolled in the WHI. The intervention promoted a goal of reducing total fat intake by 20%, by increasing vegetable, fruit, and grain consumption. The intervention group reduced fat intake by approximately 10% for more than 8.1 years of follow-up, resulting in lower estradiol and gamma-tocopherol levels, but no persistent weight loss. The incidence of invasive breast cancer was slightly lower in the intervention group, with an HR of 0.91 (95% CI, 0.83–1.01),<Reference refidx="133"/> but no difference in all-cause mortality, overall mortality, or cardiovascular disease.<Reference refidx="134"/></Para><Para id="_650">A pooled analysis of adult dietary data from eight cohort studies, which included 351,823 women with 7,377 incident breast cancers, showed minimal or no association.<Reference refidx="135"/> If the dietary data were treated as a continuous variable (based on grams of intake per day), there was no association with breast cancer. Comparing highest to lowest quartiles of intake, the pooled multivariate RRs of breast cancer were 0.93 (95% CI, 0.86–1.00) for total fruits, 0.96 (95% CI, 0.89–1.04) for total vegetables, and 0.93 (95% CI, 0.86–1.00) for total fruits and vegetables combined.</Para><Para id="_651">The Women's Healthy Eating and Living Randomized Trial <Reference refidx="136"/> examined the effect of diet on the incidence of new primary breast cancers. More than 3,000 women were enrolled and randomly assigned to an intense regimen of increased fruit and vegetable intake, increased fiber intake, and decreased fat intake, or a comparison group receiving printed materials on the “5-A-Day” dietary guidelines. After a mean of 7.3 years of follow-up, there was no reduction in new primary cancers, no difference in disease-free survival, and no difference in overall survival.</Para><Para id="_652">The potential role of specific micronutrients for breast cancer risk reduction has been examined in clinical trials, with cardiovascular disease and cancer as outcomes. The Women’s Health Study, a randomized trial with 39,876 women, found no difference in breast cancer incidence at 2 years between women assigned to take either beta carotene or placebo.<Reference refidx="137"/> In this same study, no overall effect on cancer was seen in women taking 600 IU of vitamin E every other day.<Reference refidx="138"/> The Women’s Antioxidant Cardiovascular Study examined 8,171 women for incidence of total cancer and invasive breast cancer and found no effect for vitamin C, vitamin E, or beta carotene.<Reference refidx="139"/> Two years later, a subset of 5,442 women were randomly assigned to take 1.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of B12, or placebo. After 7.3 years, there was no difference in the incidence of total invasive cancer or invasive breast cancer.<Reference refidx="140"/></Para><Para id="_653">Fenretinide <Reference refidx="141"/> is a vitamin A analog that has been shown to reduce breast carcinogenesis in preclinical studies. A phase III Italian trial compared the efficacy of a 5-year intervention with fenretinide versus no treatment in 2,972 women, aged 30 to 70 years, with surgically removed stage I breast cancer or DCIS. At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (<Emphasis>P</Emphasis> = .642), ipsilateral breast cancer (<Emphasis>P </Emphasis>= .177), incidence of distant metastases, nonbreast malignancies, and all-cause mortality.<Reference refidx="142"/></Para></SummarySection><SummarySection id="_672"><Title>Active and passive cigarette smoking</Title><Para id="_673">The potential role of active cigarette smoking in the etiology of breast cancer has been studied for more than three decades, with no clear-cut evidence of an association.<Reference refidx="143"/>  Since the mid-1990s, studies of cigarette smoking and breast cancer have more carefully accounted for secondhand smoke exposure.<Reference refidx="143"/><Reference refidx="144"/> A recent meta-analysis suggests that there is no overall association between passive smoking and breast cancer and that study methodology (ascertainment of exposure after breast cancer diagnosis) may be responsible for the apparent risk associations seen in some studies.<Reference refidx="145"/></Para></SummarySection><SummarySection id="_674"><Title>Underarm deodorants/antiperspirants</Title><Para id="_675">Despite warnings to women in lay publications that underarm deodorants and antiperspirants cause breast cancer, there is no evidence to support these concerns. A study based on interviews with 813 women who had breast cancer and 793 controls found no association between the risk of breast cancer  and the use of antiperspirants, the use of deodorants,  or the use of blade razors before these products were applied.<Reference refidx="146"/>  In contrast, a study of 437 breast cancer survivors found that women who used antiperspirants/deodorants and shaved their underarms more frequently had cancer diagnosed at a significantly younger age. A possible explanation for this finding is that these women had an earlier menarche or higher levels of endogenous hormones, both known to be risk factors for breast cancer and to increase body hair.<Reference refidx="147"/> Finally, an Iraqi study of 54 women with breast cancer and 50 controls showed no association between antiperspirant use and risk of breast cancer.<Reference refidx="148"/></Para></SummarySection><SummarySection id="_676"><Title>Statins</Title><Para id="_677">Two well-conducted meta-analyses of RCTs <Reference refidx="149"/> and RCTs plus observational studies <Reference refidx="150"/> found no evidence that statin use either increases or decreases the risk of breast cancer.</Para></SummarySection><SummarySection id="_685"><Title>Bisphosphonates</Title><Para id="_686">Oral and intravenous bisphosphonates for the treatment of hypercalcemia and osteoporosis have been studied for a possible beneficial effect on breast cancer prevention.  Initial observational studies suggested that women who used these drugs for durations of approximately 1 to 4 years had a lower incidence of breast cancer.<Reference refidx="151"/><Reference refidx="152"/> <Reference refidx="153"/><Reference refidx="154"/>  These findings are confounded by the fact that women with osteoporosis have lower breast cancer risk than those with normal bone density.  Additional evidence came from studies of women with a breast cancer diagnosis; the use of these drugs was associated with fewer new contralateral cancers.<Reference refidx="155"/>  With this background, two large randomized placebo-controlled trials were done.   The Fracture Intervention Trial (FIT) treated 6,194 postmenopausal osteopenic women with either alendronate or placebo and found no difference at 3.8 years in breast cancer incidence, with incidence of 1.8% and 1.5%, respectively (HR, 1.24; CI, 0.84–1.83).  The Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PRT) examined 7,580 postmenopausal osteoporotic women with either intravenous zoledronate or placebo and found no difference at 2.8 years in breast cancer incidence, with incidence of 0.8% and 0.9%, respectively (HR, 1.15; CI, 0.7–1.89).<Reference refidx="156"/></Para></SummarySection></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. <ExternalRef xref="http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf">Available online</ExternalRef>. Last accessed April 1, 2015.</Citation><Citation idx="2">Altekruse SF, Kosary CL, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2007. Bethesda, Md: National Cancer Institute, 2010. <ExternalRef xref="http://seer.cancer.gov/csr/1975_2011/">Also available online</ExternalRef>.    Last accessed June 17, 2015.</Citation><Citation idx="3" PMID="8007692" MedlineID="94276605">Boone CW, Kelloff GJ, Freedman LS: Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action. J Cell Biochem Suppl 17G: 14-25, 1993.</Citation><Citation idx="4" PMID="8137331" MedlineID="94185065">Kelloff GJ, Boone CW, Steele VE, et al.: Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 54 (7 Suppl): 2015s-2024s, 1994.</Citation><Citation idx="5" PMID="2879636" MedlineID="87102891">Knabbe C, Lippman ME, Wakefield LM, et al.: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48 (3): 417-28, 1987.</Citation><Citation idx="6" PMID="2698807" MedlineID="90214689">Parkin DM: Cancers of the breast, endometrium and ovary: geographic correlations. Eur J Cancer Clin Oncol 25 (12): 1917-25, 1989.</Citation><Citation idx="7" PMID="613235" MedlineID="78177178">Dunn JE Jr: Breast cancer among American Japanese in the San Francisco Bay area. Natl Cancer Inst Monogr 47: 157-60, 1977.</Citation><Citation idx="8" PMID="7674320" MedlineID="95404633">Kliewer EV, Smith KR: Breast cancer mortality among immigrants in Australia and Canada. J Natl Cancer Inst 87 (15): 1154-61, 1995.</Citation><Citation idx="9" PMID="3167610" MedlineID="89002187">Brinton LA, Schairer C, Hoover RN, et al.: Menstrual factors and risk of breast cancer. Cancer Invest 6 (3): 245-54, 1988.</Citation><Citation idx="10" PMID="11959894" MedlineID="21956821">Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94 (8): 606-16, 2002.</Citation><Citation idx="11" PMID="1276589" MedlineID="76207166">Smith PG, Doll R: Late effects of x irradiation in patients treated for metropathia haemorrhagica. Br J Radiol 49 (579): 224-32, 1976.</Citation><Citation idx="12" PMID="5058966" MedlineID="72107621">Trichopoulos D, MacMahon B, Cole P: Menopause and breast cancer risk. J Natl Cancer Inst 48 (3): 605-13, 1972.</Citation><Citation idx="13" PMID="5671283" MedlineID="68393154">Feinleib M: Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 41 (2): 315-29, 1968.</Citation><Citation idx="14" PMID="3189296" MedlineID="89047366">Kampert JB, Whittemore AS, Paffenbarger RS Jr: Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epidemiol 128 (5): 962-79, 1988.</Citation><Citation idx="15" PMID="13907646">Hirayama T, Wynder EL: A study of the epidemiology of cancer of the breast. II. The influence of hysterectomy. Cancer 15: 28-38, 1962 Jan-Feb.</Citation><Citation idx="16" PMID="8609646" MedlineID="96194363">Colditz GA, Rosner BA, Speizer FE: Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group. J Natl Cancer Inst 88 (6): 365-71, 1996.</Citation><Citation idx="17" PMID="7545954" MedlineID="95025896">Miki Y, Swensen J, Shattuck-Eidens D, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (5182): 66-71, 1994.</Citation><Citation idx="18" PMID="7939630" MedlineID="95025878">Futreal PA, Liu Q, Shattuck-Eidens D, et al.: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (5182): 120-2, 1994.</Citation><Citation idx="19" PMID="8091231" MedlineID="94378006">Wooster R, Neuhausen SL, Mangion J, et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 (5181): 2088-90, 1994.</Citation><Citation idx="20" PMID="8976369" MedlineID="97130606">Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92 (2): 130-4, 1996.</Citation><Citation idx="21" PMID="8460634" MedlineID="93212726">Easton DF, Bishop DT, Ford D, et al.: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52 (4): 678-701, 1993.</Citation><Citation idx="22" PMID="10213546" MedlineID="99228560">Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350 (9084): 1047-59, 1997.</Citation><Citation idx="23" PMID="12090863">Hulley S, Furberg C, Barrett-Connor E, et al.: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (1): 58-66, 2002.</Citation><Citation idx="24" PMID="12117397" MedlineID="22113237">Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (3): 321-33, 2002.</Citation><Citation idx="25" PMID="20959578">Chlebowski RT, Anderson GL, Gass M, et al.: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304 (15): 1684-92, 2010.</Citation><Citation idx="26" PMID="12824205" MedlineID="22708575">Chlebowski RT, Hendrix SL, Langer RD, et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (24): 3243-53, 2003.</Citation><Citation idx="27" PMID="23543779">Chlebowski RT, Manson JE, Anderson GL, et al.: Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 105 (8): 526-35, 2013.</Citation><Citation idx="28" PMID="15082697">Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (14): 1701-12, 2004.</Citation><Citation idx="29" PMID="21467283">LaCroix AZ, Chlebowski RT, Manson JE, et al.: Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305 (13): 1305-14, 2011.</Citation><Citation idx="30" PMID="22401913">Anderson GL, Chlebowski RT, Aragaki AK, et al.: Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13 (5): 476-86, 2012.</Citation><Citation idx="31" PMID="23048011">Schierbeck LL, Rejnmark L, Tofteng CL, et al.: Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345: e6409, 2012.</Citation><Citation idx="32" PMID="21278356">Beral V, Reeves G, Bull D, et al.: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103 (4): 296-305, 2011.</Citation><Citation idx="33" PMID="12824206" MedlineID="22708576">Li CI, Malone KE, Porter PL, et al.: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 (24): 3254-63, 2003.</Citation><Citation idx="34" PMID="21278357">Chlebowski RT, Anderson GL: The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst 103 (4): 284-5, 2011.</Citation><Citation idx="35" PMID="18448442">Prentice RL, Chlebowski RT, Stefanick ML, et al.: Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 167 (12): 1407-15, 2008.</Citation><Citation idx="36" PMID="19196674">Chlebowski RT, Kuller LH, Prentice RL, et al.: Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360 (6): 573-87, 2009.</Citation><Citation idx="37" PMID="18979196">Cronin KA, Ravdin PM, Edwards BK: Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat 117 (1): 223-4, 2009.</Citation><Citation idx="38" PMID="17442911">Ravdin PM, Cronin KA, Howlader N, et al.: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (16): 1670-4, 2007.</Citation><Citation idx="39" PMID="19217279">Parkin DM: Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 45 (9): 1649-53, 2009.</Citation><Citation idx="40" PMID="19894110">Lambe M, Wigertz A, Holmqvist M, et al.: Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 121 (3): 679-83, 2010.</Citation><Citation idx="41" PMID="20439342">Renard F, Vankrunkelsven P, Van Eycken L, et al.: Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 21 (12): 2356-60, 2010.</Citation><Citation idx="42" PMID="21060026">Farhat GN, Walker R, Buist DS, et al.: Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 28 (35): 5140-6, 2010.</Citation><Citation idx="43" PMID="21357727">DeSantis C, Howlader N, Cronin KA, et al.: Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 20 (5): 733-9, 2011.</Citation><Citation idx="44" PMID="8405198" MedlineID="94009400">John EM, Kelsey JL: Radiation and other environmental exposures and breast cancer. Epidemiol Rev 15 (1): 157-62, 1993.</Citation><Citation idx="45" PMID="3748092" MedlineID="86311126">Evans JS, Wennberg JE, McNeil BJ: The influence of diagnostic radiography on the incidence of breast cancer and leukemia. N Engl J Med 315 (13): 810-5, 1986.</Citation><Citation idx="46" PMID="1961222" MedlineID="92072632">Swift M, Morrell D, Massey RB, et al.: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325 (26): 1831-6, 1991.</Citation><Citation idx="47" PMID="16801631">Andrieu N, Easton DF, Chang-Claude J, et al.: Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 24 (21): 3361-6, 2006.</Citation><Citation idx="48" PMID="8592547" MedlineID="96172864">Bhatia S, Robison LL, Oberlin O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334 (12): 745-51, 1996.</Citation><Citation idx="49" PMID="8416252" MedlineID="93095141">Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85 (1): 25-31, 1993.</Citation><Citation idx="50" PMID="8622057" MedlineID="96208818">Sankila R, Garwicz S, Olsen JH, et al.: Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 14 (5): 1442-6, 1996.</Citation><Citation idx="51" PMID="12876089">Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290 (4): 465-75, 2003.</Citation><Citation idx="52" PMID="12837833">van Leeuwen FE, Klokman WJ, Stovall M, et al.: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (13): 971-80, 2003.</Citation><Citation idx="53" PMID="10856100" MedlineID="20314658">Obedian E, Fischer DB, Haffty BG: Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18 (12): 2406-12, 2000.</Citation><Citation idx="54" PMID="12393820" MedlineID="22282026">Fisher B, Anderson S, Bryant J, et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (16): 1233-41, 2002.</Citation><Citation idx="55" PMID="12393819" MedlineID="22282025">Veronesi U, Cascinelli N, Mariani L, et al.: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (16): 1227-32, 2002.</Citation><Citation idx="56" PMID="12192016" MedlineID="22179757">Fisher B, Jeong JH, Anderson S, et al.: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 (8): 567-75, 2002.</Citation><Citation idx="57" PMID="12420953" MedlineID="22308039">Morimoto LM, White E, Chen Z, et al.: Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 13 (8): 741-51, 2002.</Citation><Citation idx="58" PMID="15090721">Lawlor DA, Smith GD, Ebrahim S: Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 15 (3): 267-75, 2004.</Citation><Citation idx="59" PMID="12439712" MedlineID="22325580">Hamajima N, Hirose K, Tajima K, et al.: Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87 (11): 1234-45, 2002.</Citation><Citation idx="60" PMID="6866078" MedlineID="83244959">Pike MC, Krailo MD, Henderson BE, et al.: 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 303 (5920): 767-70, 1983.</Citation><Citation idx="61" PMID="8202106" MedlineID="94261144">Lambe M, Hsieh C, Trichopoulos D, et al.: Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331 (1): 5-9, 1994.</Citation><Citation idx="62">Henderson BE, Pike MC, Ross RK, et al.: Epidemiology and risk factors. In: Bonadonna G, ed.: Breast Cancer: Diagnosis and Management. Chichester, NY: John Wiley &amp; Sons, 1984, pp 15-33.</Citation><Citation idx="63" PMID="2593165" MedlineID="90079979">Gail MH, Brinton LA, Byar DP, et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (24): 1879-86, 1989.</Citation><Citation idx="64" PMID="12133652" MedlineID="22129315">Col: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360 (9328): 187-95, 2002.</Citation><Citation idx="65" PMID="10405840" MedlineID="99334312">Furberg H, Newman B, Moorman P, et al.: Lactation and breast cancer risk. Int J Epidemiol 28 (3): 396-402, 1999.</Citation><Citation idx="66" PMID="8072034" MedlineID="94351760">Bernstein L, Henderson BE, Hanisch R, et al.: Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 86 (18): 1403-8, 1994.</Citation><Citation idx="67" PMID="11319168" MedlineID="21218686">Friedenreich CM: Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev 10 (4): 287-301, 2001.</Citation><Citation idx="68" PMID="9113929" MedlineID="97258685">Thune I, Brenn T, Lund E, et al.: Physical activity and the risk of breast cancer. N Engl J Med 336 (18): 1269-75, 1997.</Citation><Citation idx="69" PMID="11491277" MedlineID="21383360">Adams-Campbell LL, Rosenberg L, Rao RS, et al.: Strenuous physical activity and breast cancer risk in African-American women. J Natl Med Assoc 93 (7-8): 267-75, 2001 Jul-Aug.</Citation><Citation idx="70" PMID="1920492" MedlineID="92015314">Nayfield SG, Karp JE, Ford LG, et al.: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83 (20): 1450-9, 1991.</Citation><Citation idx="71" PMID="7979855" MedlineID="95070642">Love RR, Barden HS, Mazess RB, et al.: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154 (22): 2585-8, 1994.</Citation><Citation idx="72" PMID="8558225" MedlineID="96140284">Powles TJ, Hickish T, Kanis JA, et al.: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1): 78-84, 1996.</Citation><Citation idx="73" PMID="9182975" MedlineID="97325963">Costantino JP, Kuller LH, Ives DG, et al.: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89 (11): 776-82, 1997.</Citation><Citation idx="74" PMID="1912833" MedlineID="92004283">McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303 (6800): 435-7, 1991.</Citation><Citation idx="75" PMID="8350363" MedlineID="93353542">Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85 (17): 1398-406, 1993.</Citation><Citation idx="76" PMID="8133536" MedlineID="94180408">Fisher B, Costantino JP, Redmond CK, et al.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (7): 527-37, 1994.</Citation><Citation idx="77" PMID="11036892" MedlineID="20488363">Bergman L, Beelen ML, Gallee MP, et al.: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356 (9233): 881-7, 2000.</Citation><Citation idx="78" PMID="12559863">Cuzick J, Powles T, Veronesi U, et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (9354): 296-300, 2003.</Citation><Citation idx="79">Redmond CK, Wickerham DL, Cronin W, et al.: The NSABP breast cancer prevention trial (BCPT): a progress report. [Abstract] Proceedings of the American Society of Clinical Oncology  12: A-78, 69, 1993.</Citation><Citation idx="80" PMID="9747868" MedlineID="98418640">Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (18): 1371-88, 1998.</Citation><Citation idx="81" PMID="16288118">Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 (22): 1652-62, 2005.</Citation><Citation idx="82" PMID="9672274" MedlineID="98336018">Powles T, Eeles R, Ashley S, et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (9122): 98-101, 1998.</Citation><Citation idx="83" PMID="9672273" MedlineID="98336017">Veronesi U, Maisonneuve P, Costa A, et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352 (9122): 93-7, 1998.</Citation><Citation idx="84" PMID="12243915">Cuzick J, Forbes J, Edwards R, et al.: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (9336): 817-24, 2002.</Citation><Citation idx="85" PMID="17312305">Powles TJ, Ashley S, Tidy A, et al.: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 (4): 283-90, 2007.</Citation><Citation idx="86" PMID="17470740">Veronesi U, Maisonneuve P, Rotmensz N, et al.: Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99 (9): 727-37, 2007.</Citation><Citation idx="87" PMID="15047916">Martino S, Costantino J, McNabb M, et al.: The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 9 (2): 116-25, 2004.</Citation><Citation idx="88" PMID="17312304">Cuzick J, Forbes JF, Sestak I, et al.: Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 (4): 272-82, 2007.</Citation><Citation idx="89" PMID="10376613" MedlineID="99303106">Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (9169): 1993-2000, 1999.</Citation><Citation idx="90" PMID="10068418" MedlineID="99156327">Khovidhunkit W, Shoback DM: Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 130 (5): 431-9, 1999.</Citation><Citation idx="91" PMID="11261828" MedlineID="21158280">Cauley JA, Norton L, Lippman ME, et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 (2): 125-34, 2001.</Citation><Citation idx="92" PMID="10376571" MedlineID="99303064">Cummings SR, Eckert S, Krueger KA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (23): 2189-97, 1999.</Citation><Citation idx="93" PMID="15572757">Martino S, Cauley JA, Barrett-Connor E, et al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (23): 1751-61, 2004.</Citation><Citation idx="94" PMID="18544744">Grady D, Cauley JA, Geiger MJ, et al.: Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 100 (12): 854-61, 2008.</Citation><Citation idx="95" PMID="16754727">Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2727-41, 2006.</Citation><Citation idx="96" PMID="16754728">Land SR, Wickerham DL, Costantino JP, et al.: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2742-51, 2006.</Citation><Citation idx="97" PMID="12090977" MedlineID="22086512">The ATAC Trialists' Group. Arimidex, tamoxifen alone or in combination: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (9324): 2131-9, 2002.</Citation><Citation idx="98" PMID="14551341" MedlineID="22965325">Goss PE, Ingle JN, Martino S, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (19): 1793-802, 2003.</Citation><Citation idx="99" PMID="15014181">Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (11): 1081-92, 2004.</Citation><Citation idx="100" PMID="21639806">Goss PE, Ingle JN, Alés-Martínez JE, et al.: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364 (25): 2381-91, 2011.</Citation><Citation idx="101" PMID="24333009">Cuzick J, Sestak I, Forbes JF, et al.: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383 (9922): 1041-8, 2014.</Citation><Citation idx="102" PMID="9887158" MedlineID="99091091">Hartmann LC, Schaid DJ, Woods JE, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 (2): 77-84, 1999.</Citation><Citation idx="103" PMID="25408966">Kummerow KL, Du L, Penson DF, et al.: Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 150 (1): 9-16, 2015.</Citation><Citation idx="104" PMID="10469748" MedlineID="99400811">Rebbeck TR, Levin AM, Eisen A, et al.: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (17): 1475-9, 1999.</Citation><Citation idx="105" PMID="12023992" MedlineID="22022073">Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (21): 1609-15, 2002.</Citation><Citation idx="106" PMID="12023993" MedlineID="22022074">Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616-22, 2002.</Citation><Citation idx="107" PMID="18268356">Kauff ND, Domchek SM, Friebel TM, et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26 (8): 1331-7, 2008.</Citation><Citation idx="108" PMID="8899264" MedlineID="97054975">Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 54 (3 Suppl): 1S-106S, 1996.</Citation><Citation idx="109" PMID="12087137" MedlineID="22082198">Marchbanks PA, McDonald JA, Wilson HG, et al.: Oral contraceptives and the risk of breast cancer. N Engl J Med 346 (26): 2025-32, 2002.</Citation><Citation idx="110" PMID="15105056">Strom BL, Berlin JA, Weber AL, et al.: Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 69 (5): 353-60, 2004.</Citation><Citation idx="111" PMID="8468722" MedlineID="93225135">Wolff MS, Toniolo PG, Lee EW, et al.: Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 85 (8): 648-52, 1993.</Citation><Citation idx="112" PMID="9851382" MedlineID="99066707">Høyer AP, Grandjean P, Jørgensen T, et al.: Organochlorine exposure and risk of breast cancer. Lancet 352 (9143): 1816-20, 1998.</Citation><Citation idx="113" PMID="7802816" MedlineID="95018344">Shames LS, Munekata MT, Pike MC: Re: Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 86 (21): 1642-3, 1994.</Citation><Citation idx="114" PMID="8145274" MedlineID="94194540">Krieger N, Wolff MS, Hiatt RA, et al.: Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. J Natl Cancer Inst 86 (8): 589-99, 1994.</Citation><Citation idx="115" PMID="9345073" MedlineID="97475834">Hunter DJ, Hankinson SE, Laden F, et al.: Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 337 (18): 1253-8, 1997.</Citation><Citation idx="116" PMID="11353787" MedlineID="21253117">Laden F, Collman G, Iwamoto K, et al.: 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst 93 (10): 768-76, 2001.</Citation><Citation idx="117" PMID="11142422" MedlineID="21022030">Ward EM, Schulte P, Grajewski B, et al.: Serum organochlorine levels and breast cancer: a nested case-control study of Norwegian women. Cancer Epidemiol Biomarkers Prev 9 (12): 1357-67, 2000.</Citation><Citation idx="118" PMID="11251983" MedlineID="21150223">Laden F, Hankinson SE, Wolff MS, et al.: Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the Nurses' Health Study. Int J Cancer 91 (4): 568-74, 2001.</Citation><Citation idx="119" PMID="15051280">Beral V, Bull D, Doll R, et al.: Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 363 (9414): 1007-16, 2004.</Citation><Citation idx="120" PMID="8944006" MedlineID="97099429">Rookus MA, van Leeuwen FE: Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study. J Natl Cancer Inst 88 (23): 1759-64, 1996.</Citation><Citation idx="121" PMID="8988884" MedlineID="97130062">Melbye M, Wohlfahrt J, Olsen JH, et al.: Induced abortion and the risk of breast cancer. N Engl J Med 336 (2): 81-5, 1997.</Citation><Citation idx="122" PMID="11351314" MedlineID="21248730">Sanderson M, Shu XO, Jin F, et al.: Abortion history and breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 92 (6): 899-905, 2001.</Citation><Citation idx="123" PMID="12434288" MedlineID="22320982">Ye Z, Gao DL, Qin Q, et al.: Breast cancer in relation to induced abortions in a cohort of Chinese women. Br J Cancer 87 (9): 977-81, 2002.</Citation><Citation idx="124" PMID="12646509">Mahue-Giangreco M, Ursin G, Sullivan-Halley J, et al.: Induced abortion, miscarriage, and breast cancer risk of young women. Cancer Epidemiol Biomarkers Prev 12 (3): 209-14, 2003.</Citation><Citation idx="125" PMID="12494478" MedlineID="22381027">Erlandsson G, Montgomery SM, Cnattingius S, et al.: Abortions and breast cancer: record-based case-control study. Int J Cancer 103 (5): 676-9, 2003.</Citation><Citation idx="126" PMID="17111259">Rosenblatt KA, Gao DL, Ray RM, et al.: Induced abortions and the risk of all cancers combined and site-specific cancers in Shanghai. Cancer Causes Control 17 (10): 1275-80, 2006.</Citation><Citation idx="127" PMID="16646050">Reeves GK, Kan SW, Key T, et al.: Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer 119 (7): 1741-5, 2006.</Citation><Citation idx="128" PMID="18477486">Henderson KD, Sullivan-Halley J, Reynolds P, et al.: Incomplete pregnancy is not associated with breast cancer risk: the California Teachers Study. Contraception 77 (6): 391-6, 2008.</Citation><Citation idx="129" PMID="15095312">Lash TL, Fink AK: Null association between pregnancy termination and breast cancer in a registry-based study of parous women. Int J Cancer 110 (3): 443-8, 2004.</Citation><Citation idx="130" PMID="17452545">Michels KB, Xue F, Colditz GA, et al.: Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med 167 (8): 814-20, 2007.</Citation><Citation idx="131" PMID="165553" MedlineID="75158616">Carroll KK, Khor HT: Dietary fat in relation to tumorigenesis. Prog Biochem Pharmacol 10: 308-53, 1975.</Citation><Citation idx="132" PMID="8538706" MedlineID="96140458">Hunter DJ, Spiegelman D, Adami HO, et al.: Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. N Engl J Med 334 (6): 356-61, 1996.</Citation><Citation idx="133" PMID="16467232">Prentice RL, Caan B, Chlebowski RT, et al.: Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (6): 629-42, 2006.</Citation><Citation idx="134" PMID="16467234">Howard BV, Van Horn L, Hsia J, et al.: Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (6): 655-66, 2006.</Citation><Citation idx="135" PMID="11176915" MedlineID="21105481">Smith-Warner SA, Spiegelman D, Yaun SS, et al.: Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA 285 (6): 769-76, 2001.</Citation><Citation idx="136" PMID="17635889">Pierce JP, Natarajan L, Caan BJ, et al.: Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298 (3): 289-98, 2007.</Citation><Citation idx="137" PMID="10601381" MedlineID="20071042">Lee IM, Cook NR, Manson JE, et al.: Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 91 (24): 2102-6, 1999.</Citation><Citation idx="138" PMID="15998891">Lee IM, Cook NR, Gaziano JM, et al.: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (1): 56-65, 2005.</Citation><Citation idx="139" PMID="19116389">Lin J, Cook NR, Albert C, et al.: Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 101 (1): 14-23, 2009.</Citation><Citation idx="140" PMID="18984888">Zhang SM, Cook NR, Albert CM, et al.: Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA 300 (17): 2012-21, 2008.</Citation><Citation idx="141" PMID="8137334" MedlineID="94185068">Costa A, Formelli F, Chiesa F, et al.: Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54 (7 Suppl): 2032s-2037s, 1994.</Citation><Citation idx="142" PMID="10547391" MedlineID="20016408">Veronesi U, De Palo G, Marubini E, et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91 (21): 1847-56, 1999.</Citation><Citation idx="143">U.S. Department of Health and Human Services: The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. <ExternalRef xref="http://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm">Available online</ExternalRef>.                Last accessed April 24, 2015.</Citation><Citation idx="144">U.S. Department of Health and Human Services: The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, Centers for Disease Control and
Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006. <ExternalRef xref="http://www.ncbi.nlm.nih.gov/books/NBK44324/">Also available online</ExternalRef>.                       Last accessed   May 28, 2015.</Citation><Citation idx="145" PMID="18544575">Pirie K, Beral V, Peto R, et al.: Passive smoking and breast cancer in never smokers: prospective study and meta-analysis. Int J Epidemiol 37 (5): 1069-79, 2008.</Citation><Citation idx="146" PMID="12381712">Mirick DK, Davis S, Thomas DB: Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst 94 (20): 1578-80, 2002.</Citation><Citation idx="147" PMID="14639125">McGrath KG: An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving. Eur J Cancer Prev 12 (6): 479-85, 2003.</Citation><Citation idx="148" PMID="17037719">Fakri S, Al-Azzawi A, Al-Tawil N: Antiperspirant use as a risk factor for breast cancer in Iraq. East Mediterr Health J 12 (3-4): 478-82, 2006 May-Jul.</Citation><Citation idx="149" PMID="16391219">Dale KM, Coleman CI, Henyan NN, et al.: Statins and cancer risk: a meta-analysis. JAMA 295 (1): 74-80, 2006.</Citation><Citation idx="150" PMID="16260694">Bonovas S, Filioussi K, Tsavaris N, et al.: Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23 (34): 8606-12, 2005.</Citation><Citation idx="151" PMID="20160722">Newcomb PA, Trentham-Dietz A, Hampton JM: Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102 (5): 799-802, 2010.</Citation><Citation idx="152" PMID="20567021">Rennert G, Pinchev M, Rennert HS: Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28 (22): 3577-81, 2010.</Citation><Citation idx="153" PMID="20567009">Chlebowski RT, Chen Z, Cauley JA, et al.: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28 (22): 3582-90, 2010.</Citation><Citation idx="154" PMID="22161552">Cardwell CR, Abnet CC, Veal P, et al.: Exposure to oral bisphosphonates and risk of cancer. Int J Cancer 131 (5): E717-25, 2012.</Citation><Citation idx="155" PMID="22021667">Monsees GM, Malone KE, Tang MT, et al.: Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 103 (23): 1752-60, 2011.</Citation><Citation idx="156" PMID="25111880">Hue TF, Cummings SR, Cauley JA, et al.: Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 174 (10): 1550-7, 2014.</Citation></ReferenceSection></SummarySection><SummarySection id="_85"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (05/28/2015)</Title><Para id="_89">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_683"><Strong><SummaryRef href="CDR0000062779#_29" url="/types/breast/hp/breast-prevention-pdq">Description of the Evidence</SummaryRef></Strong></Para><Para id="_690">Added <SummaryRef href="CDR0000062779#_689" url="/types/breast/hp/breast-prevention-pdq">text</SummaryRef> to state that the rate of bilateral mastectomy among women with unilateral disease was reported to have increased from 1.9% in 1998 to 11.2% in 2011 based on data from the U.S. National Cancer Data Base (cited Kummerow et al. as reference 103).</Para><Para id="_691">Revised <SummaryRef href="CDR0000062779#_636" url="/types/breast/hp/breast-prevention-pdq">text</SummaryRef> to state that no studies have been done on the benefits of prophylactic mastectomy in the average-risk population to prevent contralateral breast cancer in women with an ipsilateral breast cancer.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/screening-prevention-board">PDQ Screening and Prevention Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062779#_AboutThis_1" url="http://www.cancer.gov/types/breast/hp/breast-prevention-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection> 
  <SummarySection id="_ContactUs_2"><Title>Questions or Comments About This Summary</Title><Para id="_ContactUs_3">If you have questions or comments about this summary, please send them to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact/email-us">E-mail Us</ExternalRef>. We can respond only to email messages written in English.</Para></SummarySection> 
  <SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about breast cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/screening-prevention-board">PDQ Screening and Prevention Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a <SummaryRef href="CDR0000304747" url="/publications/pdq/levels-evidence/screening-prevention">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Breast Cancer Prevention. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/breast/hp/breast-prevention-pdq">http://www.cancer.gov/types/breast/hp/breast-prevention-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-05-28</DateLastModified></Summary>
